## CHRISTOPHER J. KEMPER, Ph.D.

25 Dix Lane - Lawrenceville, NJ 08648 - 609-213-3038

chris kemper@pharmanavigatorsllc.com

### **CURRICULUM VITAE**

#### SUMMARY

Diverse and extensive DMPK/bioanalytical experience in the pharmaceutical industry. Solid interpersonal skills, scientific expertise, and presentation capabilities. Pioneered use of microcomputers in a laboratory environment. Developed multiple bioanalytical assays as per regulatory expectations, many easily transferred to unskilled hands. Served on numerous project teams as the DMPK representative for drug development. Highly active in DMPK discussion groups in the US and Europe. Have given successful scientific presentations throughout the US, Europe, and Japan. Led in the incorporation of multiple suppliers of services in integrated drug development programs. Highly active in scientific rationale and practical application of DMPK experiments in drug discovery and development. Core skills include:

- Technology Leadership
- People Management
- Strategic Business Planning
- Scientific and Process Innovation
- Service to the DMPK Community
- Integrity and Commitment

### PROFESSIONAL EXPERIENCE

Pharma Navigators, LLC, Lawrenceville, NJ **Primary Consultant and Founder** (see www.pharmanavigatorsllc.com)

October 2010 to Present

TAYLOR TECHNOLOGY INC., Princeton, NJ (A subsidiary of PharmaNet DGI)

January 2009 to September 2010

## **Director, Bioanalytical Services**

- Developed and managed a full preliminary non-clinical NDA package for a combination dermal product (3 active ingredients) involving 4 subcontractors and approved by the FDA under Chapter 505(b)(2). Clinical recommendations also approved
- Organized/moderated 3 symposia
- Collaborated in a novel protein binding assay
- Completed book chapter on bioanalytical strategies
- Highly active in advising and promoting drug discovery PK programs

## PHARMANET DEVELOPMENT GROUP, INC.

September 2002 to January 2009

## Senior Director, Business Development, Discovery Pharmacokinetics

- Established collaborations with laboratories providing services PharmaNet did not provide
- Heavily involved in biomarker programs for nutritional status and breast cancer
- Multiple presentations in the US, Japan and Europe
- Assisted in creating the European Bioanalytical Forum
- Raised the reputation of DVDMDG to international status
- Led business development team in innovator sales

## LC RESOURCES, INC., McMinnville, Oregon

## **Vice President, Technology Development**

- Represented laboratory to external clients
- Investigated new service lines
- Supported first GLP assay development
- Doubled number of clients first year

April 2000 to September 2002

# PHOENIX INTERNATIONAL LIFE SCIENCES, Montreal, Quebec, Canada Senior Director, Business Development

**April 1994 to March 2000** 

- Instituted and supported rapid throughput and in vitro programs
- Wrote in vitro program business plan
- Outlined in vitro data management needs
- Created and supported the bioanalytical team for ultra-high throughput support of Celebrex
- Integrated bioanalytical and clinical portions for several innovator clients
- Led the business development team in innovator sales

## R.W. JOHNSON PHARMACEUTICAL, RESEARCH INSTITUTE, Raritan, NJ Principal Scientist, Drug Metabolism

March 1989 to April 1994

- Oversaw a DMPK laboratory with up to four reports, including a Ph.D.
- Involved in multiple project teams
- Created an in vitro program
- Instituted and oversaw outsourcing program
- Prepared documents for FDA review and developed and delivered presentations supporting retinoid and antifungal products
- Supported retinoid programs against regulatory challenges
- Established process for rapid study throughput, from study initiation approval to final report, for clinical studies

## WYETH AYERST RESEARCH, Radnor PA and Princeton, NJ Group Leader, Drug Disposition

September 1983 to March 1989

- Introduced microcomputers into a laboratory environment
- Created a new laboratory in a brand new facility
- Oversaw a DMPK laboratory with up to 6 direct reports, developing multiple bioanalytical assays
- Beta tested the HP 5890 GC-NPD.
- Instituted GLP processes
- Developed a series of polyol assays in multiple matrices for use as biomarkers in an aldose reductase program for diabetic/galactosemia treatment. The assays were robust enough to be reproduced in untrained hands.

### **Additional Experience:**

**GENERAL ELECTRIC**, Noryl Plastics Research and Development **Chemical Technician** 

**STERLING WINTHROP RESEARCH INST.**, Department of Drug Metabolism **Research Technician** 

**U.S. Navy**, U.S.S. Mullinnix, DD 944 **Operations Specialist 3c** Honorable Discharge

#### **EDUCATION**

Ph.D. in Pharmacology, University of Louisville Medical Center
Area of expertise: drug metabolism and pharmacokinetics
B.S. in Chemistry, Rensselaer Polytechnic Institute
Fall 2017 - M.S. in Pharmacometrics, University of Maryland (Baltimore)

Awards, memberships, publications and presentations available upon request.